

1 **Title:** HIV testing by public health centers and municipalities, and new HIV cases during the COVID-19  
2 pandemic in Japan

3 **Authors**

4 Keisuke Ejima, PhD<sup>1,2,\*</sup>, Yoshiaki Koizumi, MD<sup>3</sup>, Nao Yamamoto, MPH<sup>4</sup>, Molly Rosenberg, PhD<sup>1</sup>, Christina  
5 Ludema, PhD<sup>1</sup>, Ana I. Bento, PhD<sup>1</sup>, Daisuke Yoneoka, PhD<sup>2,5,6</sup>, Seiichi Ichikawa, PhD<sup>7</sup>, Daisuke  
6 Mizushima, MD, PhD<sup>3</sup>, and Shingo Iwami, PhD<sup>8,9,10,11,12,\*</sup>

7 **Affiliations**

8 <sup>1</sup>Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington,  
9 IN, USA.

10 <sup>2</sup>Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

11 <sup>3</sup>AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

12 <sup>4</sup>School of Human Evolution and Social Change, Arizona State University, Arizona, USA.

13 <sup>5</sup>Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan

14 <sup>6</sup>Graduate School of Public Health, St. Luke's International University, Tokyo, Japan

15 <sup>7</sup>Institute for Consumer Sciences and Human Life, Kinjo Gakuin University, Nagoya, Japan

16 <sup>8</sup>Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan.

17 <sup>9</sup>MIRAI, JST, Saitama, Japan.

18 <sup>10</sup>Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan.

19 <sup>11</sup>NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.

20 <sup>12</sup>Science Groove Inc., Fukuoka, Japan.

21 \* Corresponding authors: Keisuke Ejima, Email: [kejima@iu.edu](mailto:kejima@iu.edu), Address: PH158A, 1025 E 7th St,

22 Bloomington, IN 47405, USA, TEL: (812) 855-9172; Shingo Iwami, [siwami@kyushu-u.org](mailto:siwami@kyushu-u.org), Address: 744

23 Motooka Nishi-ku Fukuoka, 819-0395, Japan, TEL: +81 (092) 802-4296

24 **Research in context**

25 **Evidence before this study**

26 Before this study, we searched PubMed, Medline, and Google Scholar on Oct 12, 2020, for articles  
27 investigated the number of HIV test and HIV cases during the COVID-19 pandemic in Japan, using the  
28 search terms “novel coronavirus” or “SARS-CoV-2”, and “HIV” or “AIDS”, and “Japan”, with no time  
29 restrictions. We found no published work relevant to our study.

30 **Added value of this study**

31 During the COVID-19 pandemic in Japan, the public health centers and municipalities temporarily  
32 suspended facility-based HIV testing to concentrate their limited resources to COVID-19 testing. We  
33 investigated the impact of the COVID-19 pandemic on the number of HIV tests in public health centers and  
34 municipalities, and on the number of HIV cases with and without AIDS diagnosis. We confirmed that the  
35 number of the test declined in the second quarter (April to June) of 2020, and the proportion of HIV with  
36 AIDS diagnosis among all HIV cases increased during the same period.

37 **Implications of all the available evidence**

38 Providing sufficient HIV testing opportunities even during the pandemic, when facility-based testing is  
39 challenging, is necessary for better clinical and public health outcomes. Self-testing and home specimen  
40 collection (e.g. dried blood spot or oral fluid test) could be a key to fill the gap between the need for HIV  
41 testing and the constraints related to the COVID-19 outbreak.

42

## 13 **Abstract**

### 14 **Background:**

15 During the COVID-19 outbreak, medical resources were primarily allocated to COVID-19, which might  
16 have reduced facility capacity for HIV testing. Further, people may have opted against HIV testing during  
17 this period to avoid COVID-19 exposure. We investigate the influence of the COVID-19 pandemic on HIV  
18 testing and its consequences in Japan.

### 19 **Methods:**

20 We analysed quarterly HIV/AIDS-related data from 2015 to the second quarter of 2020 using an anomaly  
21 detection approach. The data included the number of consultations that public health centers received, the  
22 number of HIV tests performed by public health centers or municipalities, and the number of newly reported  
23 HIV cases with and without AIDS diagnosis. As sensitivity analyses, we performed the same analysis for  
24 two subgroups: men who have sex with men (MSM) and non-Japanese.

### 25 **Findings:**

26 The number of HIV tests (9,584 vs. 35,908 in the year-before period) and consultations (11,689 vs. 32,565)  
27 performed by public health centers significantly declined in the second quarter of 2020, while the proportion  
28 of HIV cases with AIDS diagnosis among all HIV cases (36.2% vs. 26.4%) significantly increased after  
29 removing the trend and seasonality effects. The number of HIV cases without AIDS diagnosis numerically  
30 decreased (166 vs. 217), although the reduction was not significant. We confirmed similar trend for the  
31 MSM and non-Japanese groups.

### 32 **Interpretation:**

33 The current HIV testing system including public health centers misses more HIV cases at the early phase of  
34 the infection during the pandemic. Given that the clear epidemiological picture of HIV incidence during the  
35 pandemic is still uncertain, continuously monitoring the situation as well as securing sufficient test resources  
36 using self-test is essential.

### 37 **Funding:**

38 Japan Society for the Promotion of Science, Japan Science and Technology Agency, Japan Agency for  
39 Medical Research and Development.

70 **Keywords:**

71 SARS-CoV-2, COVID-19, HIV/AIDS, HIV test accessibility

## 72 **Introduction**

73 The ongoing COVID-19 pandemic has had broad influences on lifestyle and health issues beyond COVID-  
74 19. There have been positive impacts, such as a curtailed 2019/2020 influenza season in Japan (1), which  
75 could be partially explained by measures taken to constrain the COVID-19 outbreak. Due to reduced  
76 economic activity and human mobility during lockdown, air pollution, which is a risk factor of pulmonary  
77 diseases, was temporally improved in China (2). However, there are many problems caused by risk  
78 mitigating interventions for COVID-19, many of which are under investigation. Fear and anxiety about this  
79 new disease and changed lifestyle have been stressful for many people, which has worsened mental health  
30 (3-5).

31 Further, during this pandemic period, non-COVID-19 diseases have been at a lower priority for treatment  
32 because medical resources have been disproportionately allocated to treat COVID-19 patients in many  
33 health care facilities and the capacity to care for non-COVID-19 disease has been limited. Moreover, health  
34 care facilities need to balance the benefits of providing care for non-critical conditions with minimizing the  
35 risk of COVID-19 infections for both health care professionals and patients (6).

36 People living with HIV infections have better outcomes with early diagnosis and connection to antiretroviral  
37 treatment. Early diagnosis is also key to preventing onward transmission because early infection is  
38 characterized by high viral load and receiving an HIV diagnosis facilitates behavioural change. However,  
39 Lagat et al. reported a decline in HIV test volume in Kenya due to many barriers related to COVID-19, such  
40 as lack of funds to visit clinics and fear of COVID-19 infection at clinics (7).

41 To increase HIV testing opportunities, in the United States the CDC is recommending self-testing of HIV or  
42 home specimen collection (e.g. dried blood spot or oral fluid test) to avoid COVID-19 infection risk  
43 associated with face-to-face testing service (8). In Japan, the number of self-collection-based HIV tests has  
44 increased, though the majority of tests are still conducted at public health centers and clinics (i.e., facility-  
45 based testing). However, during the pandemic, public health centers and clinics have been overwhelmed by  
46 COVID-19 PCR testing and administrative work and many have temporally suspended or limited HIV  
47 testing.

18 AIDS is usually diagnosed by the specific symptoms and the average incubation period is 10 years (9, 10).  
19 Therefore, the impact of the pandemic on the number of reported HIV cases with AIDS diagnosis will not be  
20 substantial in a short-term period (< 1 year). In contrast, the median time interval between HIV infection to  
21 the diagnosis without AIDS symptoms is 1.0 years in Tokyo, Japan (11), thus the impact of shortage of the  
22 HIV test on the number of HIV cases without AIDS diagnosis will be observed even if the pandemic does  
23 not continue over a year.

24 We assessed temporal patterns in HIV testing during the first two quarters of 2020: 1) number of HIV  
25 consultations received by public health centers, 2) number of tests performed at public health centers and  
26 municipalities, 3) number of newly reported HIV cases without AIDS diagnosis, and 4) number of newly  
27 reported HIV cases with AIDS diagnosis. Further, we assessed whether the proportion of HIV cases with  
28 AIDS diagnosis among new HIV cases increased.

## 29 **Methods**

### 30 **Data**

31 HIV/AIDS-related data were extracted from the quarterly report from the National AIDS Surveillance  
32 Committee from the first quarter of 2015 to the second quarter of 2020 (12). The data included: (1) the  
33 number of HIV/AIDS-related consultations at public health centers, (2) the number of HIV antibody tests  
34 performed at public health centers or by municipalities, (3) the number of reported HIV cases with and  
35 without AIDS diagnosis in Japan. We further extracted the data of HIV cases with and without AIDS  
36 diagnosis for the following two subgroups: men who have sex with men (MSM) and non-Japanese, because  
37 MSM accounts for about 70% of the newly reported HIV cases (12), and foreigners are considered  
38 vulnerable during disasters due to language barriers (13). The data on the number of tests and consultations  
39 for these subgroups were not available.

40 Note that HIV cases with AIDS diagnosis here represent new cases of HIV identified at late-stages,  
41 compatible with an AIDS diagnosis. Thus, this number does not include HIV cases with AIDS diagnosis that  
42 were previously diagnosed and progressed to AIDS. To rephrase, the new HIV cases here are divided into  
43 two categories: early diagnosis (HIV cases without AIDS diagnoses) and late diagnosis (HIV cases with  
44

25 AIDS diagnoses). HIV tests at clinics/hospitals and self-testing are also available in Japan. Thus, the number  
26 of HIV testing performed by public health centers or municipalities was used to examine the trend of  
27 facility-based tests, rather than capturing the total number of HIV tests or examining the proportion of HIV  
28 positive cases among all the HIV tests.

### 29 **Anomaly detection**

30 We applied an anomaly detection approach to those longitudinal data to identify the period when the number  
31 of HIV related consultations, HIV antibody tests, and new HIV cases with and without AIDS diagnosis were  
32 disrupted. Further, we tested when the proportion of HIV cases with AIDS diagnosis among all new HIV  
33 cases were disrupted. First, each longitudinal data was decomposed into seasonal, trend, and remainder  
34 components by seasonal-trend decomposition using LOESS (STL)(14). In STL, LOESS smoothing was  
35 iteratively used to determine the trend component. After removing the trend component, LOESS smoothing  
36 was again used to extract the seasonal component (one-year cycle). The trend component was tested whether  
37 it had an increasing or decreasing trend using a non-parametric Spearman test (15). The remainder was  
38 analyzed with an anomaly detection method, the Generalized Extreme Studentized Deviate Test (GESD),  
39 which identified outliers progressively using the deviation from mean as a test statistic (16). A statistical  
40 significance level was set at 0.05. All analyses were performed on the statistical computing software R 4.0.1  
41 (R Development Core Team) with the library ‘anomalize’.

## 42 43 **Results**

44 **Figure 1** shows the observed data points and the computed normal range (the shaded area). We observed a  
45 significant downward trend in HIV cases with or without AIDS diagnosis (**Figure 1A**), all the HIV cases  
46 (**Figure 1C**), and the number of consultations (**Figure 1E**) over the period examined (from the first quarter  
47 of 2015 to the second quarter of 2020). The trend in number of tests was not significant during the period  
48 (**Figure 1D**). The proportion of HIV cases with AIDS diagnosis among all the HIV cases showed a  
49 significant downward trend during the period (**Figure 1F**), suggesting that more HIV cases have been  
50 diagnosed in the early phase of infection recently. Regarding anomaly by the last quarter of 2019 (i.e.,

51 before the COVID-19 pandemic), there are a couple of data points that significantly deviated from the  
52 normal range. However, the magnitude of the deviation of those numbers was modest.

53 We did not observe deviation in any numbers in the first quarter of 2020. However, in the second quarter,  
54 the numbers of HIV tests and HIV consultations significantly declined (**Figure 1DE**), which is compatible  
55 with a public health infrastructure overwhelmed by COVID-19 related work. In contrast, the proportion of  
56 HIV cases with AIDS diagnosis among all HIV cases significantly increased (**Figure 1F**). Intriguingly, the  
57 number of HIV cases with AIDS diagnosis in the second quarter of 2020 showed the same trend as before  
58 (**Figure 1B**). The number of HIV cases without AIDS diagnosis numerically decreased in the second quarter  
59 of 2020 (**Figure 1A**), however it was not significant. It is worth noting that the number of HIV cases without  
60 AIDS diagnosis did not decline as much as the number of tests (the former dropped 23.5%, whereas the  
61 latter dropped 73.3% compared with the year-before period). This might be because more HIV cases with  
62 acute symptoms (i.e., fever) visited clinics for viral test for SARS-CoV-2 and HIV infection was  
63 subsequently diagnosed.

64 As a sensitivity analysis, we examined the longitudinal data of HIV cases with and without AIDS diagnosis  
65 of two subgroups: men who have sex with men (MSM) and non-Japanese. We confirmed the same  
66 downward trend for the MSM population as for the total population (**Figure 2A-C**) in terms of newly  
67 reported HIV cases with and without AIDS diagnosis. On contrary, the HIV cases without AIDS diagnosis  
68 and all HIV cases among non-Japanese were in upward trend (**Figure 3AC**). The number of HIV cases  
69 without AIDS diagnosis numerically decreased, whereas HIV cases with AIDS diagnosis numerically  
70 increased or were in the same trend as before in these two populations in the second quarter of 2020 (**Figure**  
71 **2AB and 3AB**). As a result, the proportion of HIV cases with AIDS diagnosis among all positive cases also  
72 numerically increased in the second quarter of 2020 in these two subgroups (**Figure 2D and 3D**); however,  
73 they were not significant, which might be due to the small sample size. The proportion of HIV cases among  
74 MSM and non-Japanese populations relative to total HIV cases was consistent over time including the  
75 second quarter of 2020 (**Figure 2E and 3E**).

76

## 77 **Discussion**



78 A significant anomaly was identified in the number of tests and consultations performed by public health  
79 centers and municipalities, the proportion of HIV cases with AIDS diagnosis among new HIV cases in the  
80 second quarter of 2020 after removing seasonality and trend, which corresponds to the period of COVID-19  
81 pandemic in Japan. Further, the number of HIV cases without AIDS diagnosis numerically decreased in the  
82 second quarter of 2020, although it was not significant. Under the COVID-19 pandemic situation, public  
83 health centers temporally suspended HIV tests. Further, people might have skipped the testing at public  
84 health centers because of the fear of COVID-19 infection or the state of emergency. The temporal change in  
85 the number of HIV tests, the number of HIV cases without symptoms, and the proportion of HIV cases with  
86 AIDS diagnosis may reflect such temporal change in HIV testing system in public health centers and  
87 municipalities.

88 We need to interpret the results carefully. First, we have analyzed the number of tests performed by public  
89 health centers and municipalities. However, this type of test accounts for less than half of the tests  
90 performed in Japan. For example, self-collection-based tests (mostly using dried blood spot) are increasing,  
91 and tests are available in clinics and hospitals; however, the count of those tests was not available. It is  
92 probable that the number of different types of HIV test has increased during the same period as  
93 compensation for the reduction in the number of tests performed by public health centers and municipalities.  
94 Second, we do not know the full picture of the impact of the pandemic on HIV epidemiology. We have used  
95 the number of reported HIV cases; however, there is likely a substantial proportion of undiagnosed cases,  
96 and it is uncertain whether the number and the proportion of undiagnosed cases changed during the  
97 pandemic. It is possible that the incidence increased (or decreased) during the pandemic. Therefore, even  
98 though the number of new HIV cases did not change dramatically, it does not indicate that the number of  
99 tests is sufficient to identify all HIV patients. Indeed, the number of reported HIV positive cases without  
100 progressed to AIDS in the second quarter of 2020 was the lowest in the last five years and the proportion of  
101 HIV cases with AIDS diagnosis significantly increased. It raises a concern that the testing opportunities  
102 might not be sufficient to fully capture the epidemiological situation of HIV/AIDS during the pandemic in  
103 Japan. Because most of the HIV cases with AIDS diagnosis are identified in clinics or hospitals due to  
104 specific symptoms, HIV cases with AIDS diagnosis are less prone to being affected by healthcare avoidance

15 even under the pandemic. Indeed, the number of HIV cases with AIDS diagnosis was in the same trend as  
16 before the pandemic. We need to keep monitoring the situation as well as adapting testing strategies to work  
17 in these unusual circumstances.

18 As the pandemic continues, we do not know how long the HIV testing opportunities provided by public  
19 health centers could be disrupted and how it could affect HIV spread. Given that early detection and  
20 treatment initiation for HIV is lifesaving, providing sufficient HIV testing opportunities is important.  
21 UNAIDS has a proposed treatment target, “90-90-90” to control the HIV epidemic (17). A part of the target  
22 is that “By 2020, 90% of all people living with HIV will know their HIV status.” If the COVID-19  
23 pandemic continuously disrupts testing opportunities, diagnosing 90% of people living with HIV might be  
24 difficult to achieve. Self-testing and home specimen collection could be a key to fill the gap between the  
25 need for HIV testing and the constraints related to the COVID-19 outbreak.

26 The strength of this study is that we used the quarterly HIV/AIDS reports in Japan, which include all the  
27 diagnosed cases as physicians are required to report all diagnosed cases under the Infectious Diseases  
28 Control Law(18). Further, the cases reported as HIV cases with AIDS diagnosis include only the cases of  
29 newly diagnosed HIV infection co-occurring with AIDS. Therefore, we could quantify the proportion of  
30 patients presenting with AIDS at the time of diagnosis, which captures late-presentation for diagnosis and is  
31 more likely if testing resources are not accessible.

32 A limitation of this study is that we were not able to account for the heterogeneous epidemiology of HIV  
33 between different regions. Higher HIV incidence has been observed in urban areas such as Tokyo and Osaka  
34 compared with rural areas. Thus, public health centers in urban areas have allocated budgetary resources  
35 towards HIV testing, whereas this has not been prioritized in rural areas. During the pandemic, the testing  
36 opportunities in rural areas may have declined even further than urban areas. Our study mainly focused on  
37 HIV cases with and without AIDS diagnosis and testing regardless of the patients’ characteristics. One of  
38 the concerns in this pandemic is that more vulnerable populations, such as sex workers, low-income  
39 populations, younger population, in addition to foreigners, may have experienced disproportionate harms.  
40 Further studies should focus on these populations and identify barriers to testing. We used only the number  
41 of tests performed by public health centers and municipalities, thus self-tests and home specimen collection,

32 which are increasingly popular, and tests performed in clinics and hospitals were not counted. Further  
33 investigation is necessary to focus on these types of tests to fully understand the response of the HIV testing  
34 system to COVID-19 in Japan. We demonstrated that the uptake of HIV testing provided by public health  
35 centers and municipalities declined; further, HIV cases without AIDS diagnosis during the COVID-19  
36 pandemic numerically decreased and the proportion of HIV cases with AIDS diagnosis increased. Thus, it  
37 will be critical to provide sufficient HIV testing opportunities and keep sustained attention on the  
38 unpredictable and previously unobserved public health consequences of the interactions between the dual  
39 COVID-19 and HIV epidemics.

40

41 **Author contributions:** Conceived and designed the study: KE SIwami. Analysed the data: KE initially  
42 analysed the data, and NY and DY verified the analyses. Wrote the paper: KE YK NY MR CL AIB DY  
43 SIchikawa DM SIwami. All authors read and approved the final manuscript.

44

45 **Declaration of interests:** The authors declare that they have no competing interests.

46

## 17 **Acknowledgments**

18 This study was supported in part by Grants-in-Aid for JSPS Scientific Research (KAKENHI) Scientific  
19 Research B 18KT0018 (to S.Iwami), 18H01139 (to S.Iwami), 16H04845 (to S.Iwami), Scientific Research  
20 in Innovative Areas 20H05042 (to S.Iwami), 19H04839 (to S.Iwami), 18H05103 (to S.Iwami); AMED J-  
21 PRIDE 19fm0208006s0103 (to S.Iwami), 19fm0208014h0003 (to S.Iwami), 19fm0208019h0103 (to  
22 S.Iwami); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.Iwami); Research Program on  
23 Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to S.Iwami); 19fk0210036h0502 (to  
24 S.Iwami); JST MIRAI (to S.Iwami).

## 25 **Competing Interest Statement**

26 The authors declare that they have no competing interests.

27

## 58 References

- 59 1. Sakamoto H, Ishikane M, Ueda P. Seasonal Influenza Activity During the SARS-CoV-2 Outbreak in  
60 Japan. *JAMA*. 2020;323(19):1969-71.
- 61 2. He G, Pan Y, Tanaka T. The short-term impacts of COVID-19 lockdown on urban air pollution in  
62 China. *Nature Sustainability*. 2020.
- 63 3. Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N, et al. How mental health care  
64 should change as a consequence of the COVID-19 pandemic. *The Lancet Psychiatry*.
- 65 4. Pfefferbaum B, North CS. *Mental Health and the Covid-19 Pandemic*. 2020.
- 66 5. Rosenberg M, Luetke M, Hensel D, Kianersi S, Herbenick D. Depression and loneliness during  
67 COVID-19 restrictions in the United States, and their associations with frequency of social and sexual  
68 connections. 2020:2020.05.18.20101840.
- 69 6. Centers for Disease Control and Prevention. Framework for Healthcare Systems Providing Non-  
70 COVID-19 Clinical Care During the COVID-19 Pandemic 2020 [Available from:  
71 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/framework-non-COVID-care.html>].
- 72 7. Lagat H, Sharma M, Kariithi E, Otieno G, Katz D, Masyuko S, et al. Impact of the COVID-19  
73 Pandemic on HIV Testing and Assisted Partner Notification Services, Western Kenya. *AIDS Behav*. 2020:1-  
74 4.
- 75 8. Centers for Disease Control and Prevention. *HIV Self Testing Guidance 2020* [Available from:  
76 [https://www.cdc.gov/nchhstp/dear\\_colleague/2020/dcl-042820-HIV-self-testing-guidance.html](https://www.cdc.gov/nchhstp/dear_colleague/2020/dcl-042820-HIV-self-testing-guidance.html)].
- 77 9. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. *Nature*. 1989;338(6212):251-3.
- 78 10. Muñoz A, Sabin CA, Phillips AN. The incubation period of AIDS. *AIDS (London, England)*.  
79 1997;11 Suppl A:S69-76.
- 80 11. Matsuoka S, Nagashima M, Sadamasu K, Mori H, Kawahata T, Zaitsu S, et al. Estimating HIV-1  
81 incidence in Japan from the proportion of recent infections. *Preventive Medicine Reports*. 2019;16:100994.
- 82 12. National AIDS Surveillance Committee. Quarterly report 2020 [Available from: [https://api-](https://api-net.jfap.or.jp/status/japan/index.html)  
83 [net.jfap.or.jp/status/japan/index.html](https://api-net.jfap.or.jp/status/japan/index.html)].
- 84 13. Clark E, Fredricks K, Woc-Colburn L, Bottazzi ME, Weatherhead J. Disproportionate impact of the  
85 COVID-19 pandemic on immigrant communities in the United States. *PLOS Neglected Tropical Diseases*.  
86 2020;14(7):e0008484.
- 87 14. Cleveland RB, Cleveland WS, Terpenning I. STL: A Seasonal-Trend Decomposition Procedure  
88 Based on Loess. *Journal of Official Statistics*. 1990;6(1):3.
- 89 15. Siegel S, Castellan N. *Non parametric statistics for the behavioral sciences*, Mc Graw-Mill  
90 international edition, New-York. USA; 1988.
- 91 16. Rosner B. Percentage Points for a Generalized ESD Many-Outlier Procedure. *Technometrics*.  
92 1983;25(2):165-72.
- 93 17. The Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: Treatment for all 2020  
94 [Available from: <https://www.unaids.org/en/resources/909090>].
- 95 18. Taniguchi K, Hashimoto S, Kawado M, Murakami Y, Izumida M, Ohta A, et al. Overview of  
96 infectious disease surveillance system in Japan, 1999-2005. *Journal of epidemiology*. 2007;17  
97 Suppl(Suppl):S3-S13.
- 98

09 **Figure legends**

10 **Figure 1. Number of HIV tests and consultations performed by public health center and**  
11 **municipalities, number of newly diagnosed HIV cases with and without AIDS diagnosis from 2015 to**  
12 **the first quarter of 2020:** (A) number of newly reported HIV cases without AIDS diagnosis, (B) number of  
13 newly reported HIV cases with AIDS diagnosis, (C) number of newly reported HIV cases with and without  
14 AIDS diagnosis, (D) number of HIV test performed by public health centers or municipals, (E) number of  
15 consultation received by public health centers, (F) proportion of HIV cases with AIDS diagnosis among all  
16 positive cases. The black and red circles are observed data, and the grey shaded areas corresponds to normal  
17 range. The observed data outside of the normal rage is considered abnormal and red colored.

18

19

l0 **Figure 2. Number of newly diagnosed HIV cases with and without AIDS diagnosis for MSM from**  
l1 **2015 to the second quarter of 2020:** (A) number of newly reported HIV cases without AIDS diagnosis, (B)  
l2 number of newly reported HIV cases with AIDS diagnosis, (C) number of newly reported HIV cases with  
l3 and without AIDS diagnosis, (D) proportion of HIV cases with AIDS diagnosis among all HIV cases, (E)  
l4 proportion of subpopulation among all HIV cases who are MSM. The black and red circles are observed  
l5 data, and the grey shaded areas corresponds to normal range. The observed data outside of the normal rage is  
l6 considered abnormal and red colored.

l7

l8

19 **Figure 3. Number of newly diagnosed HIV cases with and without AIDS diagnosis for foreigners from**  
20 **2015 to the second quarter of 2020:** (A) number of newly reported HIV cases without AIDS diagnosis, (B)  
21 number of newly reported HIV cases with AIDS diagnosis, (C) number of newly reported HIV cases with  
22 and without AIDS diagnosis, (D) proportion of HIV cases with AIDS diagnosis among all HIV cases, (E)  
23 proportion of subpopulation among all HIV cases who are non-Japanese. The black and red circles are  
24 observed data, and the grey shaded areas corresponds to normal range. The observed data outside of the  
25 normal range is considered abnormal and red colored.

26

27







